Gamma' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO
Identifiants
pubmed: 36299432
doi: 10.21203/rs.3.rs-2160004/v1
pmc: PMC9603834
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Blood Adv. 2021 Sep 14;5(17):3468-3477
pubmed: 34438442
Am J Emerg Med. 2021 Jan;39:173-179
pubmed: 33069541
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100727
pubmed: 33778183
Therapie. 2020 Jul - Aug;75(4):327-333
pubmed: 32425249
Circulation. 2012 Feb 14;125(6):773-81
pubmed: 22219349
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Thromb Haemost. 2011 Apr;105(4):605-9
pubmed: 21174007
N Engl J Med. 2021 Aug 26;385(9):777-789
pubmed: 34351722
Nat Rev Cardiol. 2022 Jul;19(7):475-495
pubmed: 35027697
J Cardiovasc Pharmacol Ther. 2021 Jan;26(1):12-24
pubmed: 32924567
JAMA. 2013 Oct 23;310(16):1711-20
pubmed: 24150467
Clin Chem. 2010 May;56(5):781-8
pubmed: 20348406